Linlang Guo

6PUBLICATIONS
14CO-AUTHORS
Epigenetics (incl. genome methylation and epigenomics)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 29, 2026
ETV6 Rearrangement Suppresses CDKN1B Transcription by Disrupting an Intragenic Super-Enhancer in Acute Lymphoblastic Leukemia.

|Mar 14, 2025
Targeting FOXP1 phase separation in small cell lung cancer mechanisms of chemotherapy resistance.

Yichun Tang, Yuchun Niu, Yi Chen

|Feb 01, 2023
Identifying CDC7 as a synergistic target of chemotherapy in resistant small-cell lung cancer via CRISPR/Cas9 screening.

Ling Deng, Li Yang, Shuhan Zhu

|May 31, 2022
Bioinformatic Analysis of Prognostic Value of SNTG2 with Immune Implications in Lung Adenocarcinoma.

Jian Zhou, Yang Wen, Xiangtian Chen

|Aug 08, 2020
EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma.

Weimei Huang, Anqi Lin, Peng Luo

|May 24, 2019
Integrated high-throughput analysis identifies super enhancers associated with chemoresistance in SCLC.

Jiarong Bao, Man Li, Shumei Liang

Pageof 1

Frequent Collaborators

2 joint publications

Qiongyao Wang

1 joint publications

Weimei Huang

1 joint publications

Qingwen Lyu

1 joint publications

Jian Zhang